Osi Pharmaceuticals LLC is categorized under Commercial Medical Research in Farmingdale, NY .
Osi Pharmaceuticals LLC was established in 0, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 5417112 by the NAICS.
If you are seeking more information, feel free to contact Colin Goddard, Chief Executive Officer at the company’s single location by writing to 1 Bioscience Park Drive, Farmingdale, New York NY 11735 or by phoning (631) 962-0600. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Osi Pharmaceuticals LLC |
| Contact Person: | Colin Goddard, Chief Executive Officer |
| Address: | 1 Bioscience Park Drive, Farmingdale, New York 11735 |
| Phone Number: | (631) 962-0600 |
| Website Address: | osip.com |
| Annual Revenue (USD): | Unknown |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417112 |
| Share This Business: |
Osi Pharmaceuticals LLC was started in 0 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 5417112. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Colin Goddard, Chief Executive Officer for inquiries that concern Osi Pharmaceuticals LLC by calling the company number (631) 962-0600, as your correspondence is most welcome. Additionally, the physical location of the single location of Osi Pharmaceuticals LLC can be found at the coordinates 40.75607,-73.42599 as well as the street address 1 Bioscience Park Drive in Farmingdale, New York 11735.
For its online presence, you may visit Osi Pharmaceuticals LLC’s website at osip.com and engage with its social media outlets through on Twitter and on Facebook.